Navigation Links
Acesys and Provid Announce Alliance for Medicinal Chemistry Services
Date:9/3/2008

NORTH BRUNSWICK, N.J. and NANJING, China, Sept. 3 /PRNewswire/ -- Acesys Pharmatech and Provid Pharmaceuticals Inc. announce a strategic alliance, combining the drug discovery expertise and project management capabilities of Provid in the US with the medicinal chemistry resources and favorable cost structure of Acesys in China.

The combined services available through the alliance will encompass all aspects of medicinal chemistry for clients in the pharmaceutical and biotech industries.

An experienced team at Provid will be involved in the design of programs, in the creation of novel intellectual property, and in exploratory research. Acesys will provide support for these projects with scaffold construction, hit-to-lead exploration, focused library synthesis, analog synthesis and other aspects of drug discovery.

Each project will operate via an alliance team including scientists and a program leader from Provid, a senior team leader and medicinal chemists from Acesys, and the client's representatives. Blending the US and China efforts will enable clients to benefit from the combined experience, emphasis on high quality, productivity, and sophisticated science, coupled with lower costs.

"We have explored opportunities for alliances with emerging companies in China for some time," said Dr. Gary Olson, Provid CEO, "and have been impressed by the exceptionally well-qualified and experienced drug discovery chemists that lead the Acesys organization. They have many years of successful CRO experience serving international pharmaceutical and biotech companies."

"With Provid's years of experience in medicinal chemistry and project management, Acesys will be able to provide low-cost medicinal chemistry service with uniquely high quality and high productivity," said Charles Ye, CEO and President of Acesys Pharmatech, "Provid has proved its expertise in medicinal chemistry in numerous projects, and has a great track record. The alliance will be a valuable resource to our clients."

About Provid

Provid Pharmaceuticals Inc. is a drug discovery service company that provides expert medicinal chemistry support to the biotech and pharmaceutical industries. These services aid a variety of research organizations ranging from start-ups and virtual development companies to large pharma, as well as government labs and academic groups. Provid applies world-class medicinal chemistry and drug development experience to transform the biological discoveries made by our customers into commercial opportunities.

For more details, see: http://www.providpharma.com.

About Acesys Pharmatech

Acesys Pharmatech is a contract research company that provides services in medicinal chemistry, including custom synthesis (from gram to kilogram), exploratory medicinal chemistry, and full medicinal chemistry project support. Acesys has extensive experience in library design and synthesis, using solution phase and solid-phase technology. In addition to its medicinal chemistry services, Acesys has built other alliances and collaborations that provide comprehensive pharmaceutical research outsourcing, including exploratory DMPK, preliminary toxicology and animal models for preclinical R&D. For details, visit our website: http://www.acesysweb.com.

Contacts:

Gary Olson, Ph.D.

President & CEO

Provid Pharmaceuticals Inc.

671 US Route 1, North Brunswick, NJ 08902

gary.olson@providpharma.com

732-565-1101 x 626

Charles Ye

President & CEO

Acesys Pharmatech, Ltd

5 Xinmofan Road, Technology Building B-2407, Nanjing 210009, China

yye@acesysweb.com

Tel: 908-998-1240


'/>"/>
SOURCE Provid Pharmaceuticals Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Roche Joins Forces With Enon Tabernacle Baptist Church to Provide Free Hepatitis C Testing to the Community
2. CardioDynamics Provides 2007 Shareholder Meeting Update
3. Pressure BioSciences, Inc. Reports Second Quarter 2007 Financial Results and Provides Business Update
4. Center for Molecular Medicine Only Regional Provider of Test Suggested in FDA Alert on Prescribing Codeine to Nursing Mothers
5. Reed Group to Provide MDA Internet Disability Duration Guidelines to U.S. Navy
6. ZymoGenetics Will Hold Conference Call Today at 5:00 p.m. Eastern Time to Provide Update on rThrombin
7. Baxter to Launch GARDian(TM), a Groundbreaking Initiative That Helps Provide Continued Access to GAMMAGARD for Current Patients
8. Niceware International Announces Licensed Vendor Status with ICCBBA, Inc. to Provide ISBT 128-compliant Software
9. NxStage Medical Provides Update on Medisystems Acquisition
10. VaxGen Files 2006 Financial Statements and Provides Cash Update
11. Signalife Provides Corporate Update
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... ... 2016 , ... Cancer experts from Austria, Hungary, Switzerland, and ... new and helpful biomarker for malignant pleural mesothelioma. Surviving Mesothelioma has just published ... , Biomarkers are components in the blood, tissue or body fluids that ...
(Date:6/27/2016)... , June 27, 2016  Liquid Biotech ... announced the funding of a Sponsored Research Agreement ... circulating tumor cells (CTCs) from cancer patients.  The ... in CTC levels correlate with clinical outcomes in ... These data will then be employed to support ...
(Date:6/24/2016)... ... 24, 2016 , ... While the majority of commercial spectrophotometers and fluorometers use ... 6000i models are higher end machines that use the more unconventional z-dimension of 20mm. ... from the bottom of the cuvette holder. , FireflySci has developed several Agilent ...
(Date:6/23/2016)... CAMBRIDGE, Mass. , June 23, 2016 /PRNewswire/ ... the development of novel compounds designed to target ... compound, napabucasin, has been granted Orphan Drug Designation ... in the treatment of gastric cancer, including gastroesophageal ... cancer stemness inhibitor designed to inhibit cancer stemness ...
Breaking Biology Technology:
(Date:5/3/2016)... VILNIUS, Lithuania , May 3, 2016 /PRNewswire/ ... today released the MegaMatcher Automated Biometric Identification ... deployment of large-scale multi-biometric projects. MegaMatcher ABIS can ... and accuracy using any combination of fingerprint, face ... of MegaMatcher SDK and MegaMatcher ...
(Date:4/26/2016)... , April 27, 2016 ... the  "Global Multi-modal Biometrics Market 2016-2020"  report to ... ) , The analysts forecast the ... CAGR of 15.49% during the period 2016-2020.  ... number of sectors such as the healthcare, BFSI, ...
(Date:4/14/2016)... 14, 2016 BioCatch ™, ... today announced the appointment of Eyal Goldwerger ... Goldwerger,s leadership appointment comes at a time ... the deployment of its platform at several of the ... which discerns unique cognitive and physiological factors, is a ...
Breaking Biology News(10 mins):